ストックスクリーナーアプリを入手
5.225
0.85%
-0.045
プレマーケット:
5.37
0.145
+2.78%
前日終値:
$5.27
開ける：
$5.25
24時間の取引高:
815.75K
Relative Volume:
1.24
時価総額：
$308.78M
収益：
$192.64M
当期純損益:
$2.51M
株価収益率:
99.71
EPS:
0.0524
ネットキャッシュフロー:
$12.42M
1週間 パフォーマンス:
-1.42%
1か月 パフォーマンス:
+20.11%
6か月 パフォーマンス:
+17.68%
1年 パフォーマンス:
+7.95%
1日の値動き範囲:
$5.18
$5.33
1週間の範囲:
$4.89
$5.475
52週間の値動き範囲:
$3.8092
$5.70
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
名前
Vanda Pharmaceuticals Inc
セクター
電話
202-734-3400
住所
2200 PENNSYLVANIA AVE NW, WASHINGTON
VNDA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
5.225 | 311.44M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-05 | 開始されました | B. Riley Securities | Buy |
| 2024-10-31 | 開始されました | H.C. Wainwright | Buy |
| 2024-07-11 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-02-25 | ダウングレード | Jefferies | Buy → Hold |
| 2021-05-12 | 開始されました | BofA Securities | Buy |
| 2021-01-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-10-29 | アップグレード | Citigroup | Neutral → Buy |
| 2020-06-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-03-16 | ダウングレード | Oppenheimer | Perform → Underperform |
| 2020-03-12 | アップグレード | Citigroup | Neutral → Buy |
| 2019-11-07 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-08-01 | アップグレード | Citigroup | Neutral → Buy |
| 2019-07-25 | ダウングレード | Stifel | Buy → Hold |
| 2018-12-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2018-12-04 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | 繰り返されました | Jefferies | Buy |
| 2018-11-08 | 再開されました | Jefferies | Buy |
| 2018-09-21 | 再開されました | Oppenheimer | Outperform |
| 2018-05-23 | 開始されました | Citigroup | Buy |
| 2018-01-19 | 開始されました | Seaport Global Securities | Buy |
| 2017-09-14 | 繰り返されました | Piper Jaffray | Overweight |
| 2017-06-27 | 再開されました | Piper Jaffray | Overweight |
| 2017-05-26 | 開始されました | H.C. Wainwright | Buy |
| 2017-04-12 | 開始されました | Oppenheimer | Outperform |
| 2016-11-09 | 開始されました | Aegis Capital | Buy |
| 2016-10-06 | 再開されました | Jefferies | Buy |
すべてを表示
Vanda Pharmaceuticals Inc (VNDA) 最新ニュース
Vanda Pharmaceuticals (VNDA) Soars After FDA Lifts Tradipitant H - GuruFocus
Vanda jumps as FDA lifts tradipitant partial clinical hold - Seeking Alpha
Vanda Says FDA Lifts Partial Hold on Tradipitant Motion-Sickness Study - marketscreener.com
FDA lifts partial clinical hold on Vanda’s tradipitant for motion sickness - Investing.com India
FDA Lifts Hold on Vanda’s Tradipitant Trials - TipRanks
FDA Lifts Hold on Vanda Pharmaceuticals' (VNDA) Tradipitant Stud - GuruFocus
Vanda Pharmaceuticals stock rises after FDA lifts partial clinical hold By Investing.com - Investing.com Canada
Vanda Pharma (NASDAQ: VNDA) wins FDA lift as tradipitant NDA review stays on track - Stock Titan
Will Vanda Pharmaceuticals Inc. (VM4) stock see insider accumulation2025 EndofYear Setup & High Conviction Trade Alerts - Newser
Vanda Pharmaceuticals (VNDA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
What insider trading reveals about Vanda Pharmaceuticals Inc. stockOil Prices & Verified Swing Trading Watchlist - Newser
Is Vanda Pharmaceuticals Inc. (VM4) stock attractive for growth fundsMarket Activity Report & Low Risk Growth Stock Ideas - Newser
Will Vanda Pharmaceuticals Inc. (VM4) stock benefit from mergersWeekly Stock Report & Weekly Setup with High ROI Potential - Newser
Can Vanda Pharmaceuticals Inc. (VM4) stock double in coming years2025 Risk Factors & Free Long-Term Investment Growth Plans - Newser
How Vanda Pharmaceuticals Inc. (VM4) stock reacts to new regulations2025 Volatility Report & Daily Oversold Bounce Ideas - Newser
How Vanda Pharmaceuticals Inc. (VM4) stock moves in volatile trading sessionsPortfolio Gains Summary & AI Optimized Trading Strategy Guides - Newser
How Vanda Pharmaceuticals Inc. (VM4) stock reacts to weak economy - Newser
How Vanda Pharmaceuticals Inc. (VM4) stock reacts to monetary easingProfit Target & Risk Controlled Stock Alerts - Newser
Will Vanda Pharmaceuticals Inc. stock pay special dividends - Newser
H.C. Wainwright reiterates Buy rating on Vanda Pharmaceuticals stock By Investing.com - Investing.com Canada
Vanda Pharmaceuticals (Nasdaq:VNDA) Provides Key Regulatory Update on Motion Sickness Therapy - Kalkine Media
Vanda Pharmaceuticals Says FDA Will Take More Time To Decide On Tradipitant Clinical Hold Re-Review - MSN
FDA Extends Review of Vanda Pharmaceuticals' (VNDA) Tradipitant - GuruFocus
FDA re-review of Vanda tradipitant partial clinical hold extended - Seeking Alpha
Vanda Pharmaceuticals Updates on Tradipitant FDA Review - TipRanks
Vanda Pharmaceuticals provides regulatory update on Tradipitant for motion sickness - marketscreener.com
Vanda Pharmaceuticals (VNDA) Updates on Tradipitant for Motion S - GuruFocus
Vanda Pharmaceuticals Provides Regulatory Update On Tradipitant For Motion Sickness - TradingView
Vanda Pharmaceuticals Inc Provides Regulatory Update on Tradipitant - TradingView
Vanda (Nasdaq: VNDA) details FDA hold re-review, labeling talks on tradipitant NDA - Stock Titan
Published on: 2025-11-28 08:55:55 - moha.gov.vn
Will Vanda Pharmaceuticals Inc. stock gain from government policiesJuly 2025 Sector Moves & Fast Gaining Stock Reports - BỘ NỘI VỤ
In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder (PR Newswire) - Aktiellt
Vanda Sees Sales Jump, But Losses Also Pile Up - Finimize
Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results (PR Newswire) - Aktiellt
Vanda a new buy at B. Riley on 'historic discount' - MSN
Will Vanda Pharmaceuticals Inc. (VM4) stock test record highs in 2025Wall Street Watch & Capital Efficient Trade Techniques - newser.com
Vanda Pharmaceuticals Leads 3 Promising Penny Stocks - Yahoo Finance
VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects - MSN
Vanda Pharmaceuticals: Commercial Execution Meets Pipeline Optionality (NASDAQ:VNDA) - Seeking Alpha
Vanda Reports Big Win In Wegovy Support Study, Analysts UpbeatVanda Pharmaceuticals (NASDAQ:VNDA) - Benzinga
Is Vanda Pharmaceuticals Inc. (VM4) stock trading at attractive multiples2025 Winners & Losers & Detailed Earnings Play Strategies - newser.com
Vanda Pharmaceuticals (VNDA): Evaluating Valuation After Successful Tradipitant Trial Results in GLP-1 Therapy Space - Yahoo Finance
Can Vanda Pharmaceuticals Inc. (VM4) stock withstand sector downturnsWeekly Profit Recap & Verified Technical Trade Signals - newser.com
Will Vanda Pharmaceuticals Inc. (VM4) stock announce special dividendRate Hike & Fast Exit Strategy with Risk Control - newser.com
Is Vanda Pharmaceuticals Inc. stock supported by innovation pipelineOptions Play & Weekly Return Optimization Plans - newser.com
Chart based analysis of Vanda Pharmaceuticals Inc. trendsWeekly Volume Report & Capital Protection Trading Alerts - newser.com
Will Vanda Pharmaceuticals Inc. stock benefit from infrastructure spending2025 Big Picture & Technical Entry and Exit Alerts - newser.com
Can Vanda's Upcoming Milestones Unlock Significant Growth In 2026? - RTTNews
Vanda Pharmaceuticals Inc (VNDA) 財務データ
収益
当期純利益
現金流量
EPS
1.10%
1.10%
大文字化:
|
ボリューム (24 時間):